Catalog No.
FHG62620
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Conjugation
Unconjugated
Target
5T4, TPBG, WAIF1, M6P1, 5T4 oncofetal trophoblast glycoprotein, Trophoblast glycoprotein, 5T4 oncofetal antigen, 5T4 oncotrophoblast glycoprotein, Wnt-activated inhibitory factor 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13641
Applications
ELISA, FCM, SPR
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.09% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA0571
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma., PMID:39949781
Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma., PMID:36735485
Identification of TPBG-Expressing Amacrine Cells in DAT-tdTomato Mouse., PMID:35551574
ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models., PMID:34045226
Expression and distribution of trophoblast glycoprotein in the mouse retina., PMID:31891182
Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma., PMID:31686124
Identification of PKCα-dependent phosphoproteins in mouse retina., PMID:31255707
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer., PMID:30736848
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition., PMID:30352801
Expression of 5T4 extracellular domain fusion protein and preparation of anti-5T4 monoclonal antibody with high affinity and internalization efficiency., PMID:29981846
The breast cancer antigen 5T4 interacts with Rab11, and is a target and regulator of Rab11 mediated trafficking., PMID:29549047
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy., PMID:28537896
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors., PMID:28070718
5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma., PMID:27780858
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer., PMID:27757559
Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography., PMID:27466353
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes., PMID:26319086
Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice., PMID:26180901
Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling., PMID:25738465
Evolving Strategies for Target Selection for Antibody-Drug Conjugates., PMID:25585957
TroVax in colorectal cancer., PMID:25483641
Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate., PMID:25423493
Understanding and exploiting 5T4 oncofoetal glycoprotein expression., PMID:25066861
A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate., PMID:24578215
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity., PMID:24194959
Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4., PMID:23603858
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells., PMID:23223830
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy., PMID:22127365
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells., PMID:21540235
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells., PMID:21056008
Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritis., PMID:20980737
Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients., PMID:20948436
Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity., PMID:20463598
CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells., PMID:20376365
5T4 as a target for immunotherapy in renal cell carcinoma., PMID:19954280
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma., PMID:19128501
Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial., PMID:19010868
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation., PMID:18056451
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses., PMID:17671134
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells., PMID:17507657
5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors., PMID:17484803
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated., PMID:16311730
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy., PMID:16222313
Viral vectors for cancer immunotherapy., PMID:16146772
Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia., PMID:15977177
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens., PMID:15838376
In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies., PMID:15772687
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors., PMID:12481437
Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer., PMID:12168897
Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer., PMID:12003637
For research use only. Not for human or drug use.
